Most Read Articles
19 Jun 2019
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 3 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Excessive daytime sleepiness predicts Aβ deposition

13 Sep 2018
The latest HLI survey had Hong Kong ranking last among 15 economies where "health satisfaction" was concerned.

Excessive daytime sleepiness (EDS) appears to increase the long-term risk of amyloid β (Aβ) deposition, a recent study has shown.

Using self-reports, researchers determined EDS and napping patterns in 124 community-dwelling adults (mean age 60.1±9.8 years; 50 percent female). Almost a third (29 percent) of the participants were nappers while 24 percent had EDS. There was no significant correlation between EDS and napping (p=0.24).

Pittsburgh compound B positron emission tomography scans were performed after a mean follow-up duration of 15.7±3.4 years to assess Aβ deposition. At the time of imaging, 4.8 percent (n=6) had been diagnosed with mild cognitive impairment and 34.7 percent (n=43) were positive for Aβ deposits.

Participants with self-reported EDS were significantly more likely to test positive for Aβ deposits at follow-up (56.7 percent vs 28.0 percent; p=0.004).

After adjustments for covariates, multivariable logistic regression analysis showed that the risk of Aβ deposition was 2.75 times higher in those with EDS than in those without (odds ratio [OR], 2.75; 95 percent CI, 1.09–6.95; p=0.033).

A similar trend was observed for nappers. In unadjusted analysis, those with self-reported napping were twice as likely to test positive for Aβ deposits on follow-up than non-nappers, though significance was not reached (OR, 2.01; 0.91–4.50; p=0.091). This relationship was attenuated upon controlling for covariates (OR, 1.86; 0.73–4.75; p=0.194).

The findings indicate that EDS may be a low-cost, simple and noninvasive method with which patients can be risk-stratified according to likelihood of Aβ deposition, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Jun 2019
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 3 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.